Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid

Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono, an enoyl-acyl carrier protein reductase (FabI) inhibitor, and is a first-in-class antibiotic with a novel mode of action to specifically target fatty acid synthesis in Staphylococcus spp. The efficacy, safety, and tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wittke, Frederick, Vincent, Catherine, Chen, James, Heller, Barry, Kabler, Heidi, Overcash, J. Scott, Leylavergne, François, Dieppois, Guennaëlle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508579/
https://www.ncbi.nlm.nih.gov/pubmed/32747361
http://dx.doi.org/10.1128/AAC.00250-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508579/
https://www.ncbi.nlm.nih.gov/pubmed/32747361
http://dx.doi.org/10.1128/AAC.00250-20

Ejemplares similares